An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80
Nils Glücklich(Martin Luther University Halle-Wittenberg), Patrick Garidel(Boehringer Ingelheim (Germany)), Julia Buske(Boehringer Ingelheim (Germany)), Mridula Dwivedi(Boehringer Ingelheim (Germany)), Stefan Carle(Boehringer Ingelheim (Germany)), Karsten Mäder(Martin Luther University Halle-Wittenberg)
Cited by 47
Related Papers
Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates
|Pharmaceutics|2022|93
A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery
|International Journal of Pharmaceutics|2017|55
The Hsp90 machinery facilitates the transport of diphtheria toxin into human cells
|Scientific Reports|2017|42
Assessing the polysorbate degradation fingerprints and kinetics of lipases – how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions
|European Journal of Pharmaceutical Sciences|2021|37
Nose-to-Brain delivery of insulin for Alzheimer’s disease
|ADMET & DMPK|2015|35